Casopitant
Overview[edit | edit source]
Casopitant is a neurokinin-1 receptor antagonist that has been investigated for its potential use in the prevention of chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea and vomiting (PONV). It works by blocking the action of substance P, a neuropeptide associated with the emetic reflex.
Mechanism of Action[edit | edit source]
Casopitant exerts its effects by selectively inhibiting the neurokinin-1 receptor (NK1 receptor), which is a receptor for substance P. Substance P is a key player in the vomiting reflex, and by blocking its receptor, casopitant can reduce the incidence of nausea and vomiting.
Clinical Applications[edit | edit source]
Casopitant has been primarily studied for its role in managing nausea and vomiting associated with chemotherapy and surgery. These conditions often involve the activation of the vomiting center in the brain, where substance P and the NK1 receptor play significant roles.
Chemotherapy-Induced Nausea and Vomiting (CINV)[edit | edit source]
CINV is a common side effect of cancer treatment that can significantly affect a patient's quality of life. Casopitant, as an NK1 receptor antagonist, has been evaluated in clinical trials to determine its efficacy in reducing both acute and delayed phases of CINV.
Postoperative Nausea and Vomiting (PONV)[edit | edit source]
PONV is a frequent complication following surgical procedures, particularly those involving general anesthesia. Casopitant has been investigated as a potential prophylactic treatment to prevent PONV, offering an alternative to traditional antiemetic therapies.
Pharmacokinetics[edit | edit source]
Casopitant is administered orally and undergoes extensive hepatic metabolism. The drug's pharmacokinetic profile includes a moderate half-life, allowing for once-daily dosing in clinical settings.
Development and Regulatory Status[edit | edit source]
Casopitant was developed by GlaxoSmithKline and underwent several clinical trials to assess its safety and efficacy. However, its development was eventually discontinued, and it has not been approved for clinical use in any country.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
